Article

FDA Approves Implant for Nearsightedness

Author(s):

The FDA approved a corneal implant to correct near-sightedness.

The US Food and Drug Administration (FDA) today approved a device implanted in the cornea of one eye for some patients with presbyopia. It will not work if patients do not have clear distance vision.

It is the second FDA-approved implantable corneal device for correction of near-sightedness. It is meant only for patients who have not had cataract surgery, the FDA noted.

The devices is marketed as the Raindrop Near Vision Inlay. It is made by Revision Optics, Inc. of Lake Forest, CA.

The device is not for patients with severe dry eye, active eye infection, corneal disease characterized by general thinning and cone-shaped protrusion in the center of the cornea, and certain other conditions including uncontrolled diabetes.

The implant proved safe and effective in a clinical trial of 373 patients of whom 92% were able to see with 20/40 vision or better at near distances with the inlay.

According to the FDA, the implant could be an alternative to reading glasses or bifocals.

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
© 2024 MJH Life Sciences

All rights reserved.